Novocure (NSDQ:NVCR) touted health-related quality of life analyses from a pivotal Phase III trial combining its Optune device with standard temozolomide chemotherapy for patients with newly diagnosed glioblastoma.
The data showed that adding Optune to temozolomide did not negatively impact health-related quality of life, except for itchy skin which the company attributed to skin irritation beneath Optune’s transducer arrays. The combination therapy improved deterioration-free survival of several predefined health-related quality of life scales compared to chemo alone, Novocure reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure touts quality of life data for Optune, chemo combo appeared first on MassDevice.